Subgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), versus investigator's choice of endocrine monotherapy for ER+/HER2-advanced/metastatic breast cancer (mBC).

被引：0

作者：

Kaklamani, Virginia G.

Bardia, Aditya

Aftimos, Philippe Georges

Cortes, Javier

Lu, Janice M.

Neven, Patrick

Streich, Guillermo

Montero, Alberto J.

Forget, Frederic

Mouret-Reynier, Marie-Ange

Sohn, Joohyuk

Taylor, Donatienne

Harnden, Kathleen Kiernan

Khong, Hung T.

Kocsis, Judit

Dalenc, Florence

Dillon, Patrick Michael

Tonini, Giulia

Grzegorzewski, Kris

Bidard, Francois-Clement

机构：

[1] Univ Texas Hlth Sci Ctr, Houston, TX USA

[2] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA

[3] Univ Libre Bruxelles, Inst Jules Bordet, Brussels, Belgium

[4] Quironsalud Grp, Int Breast Canc Ctr, Barcelona, Spain

[5] Univ Europea Madrid, Madrid, Spain

[6] Univ Southern Calif, Los Angeles, CA USA

[7] Univ Ziekenhuizen UZ, Leuven Canc Inst, Leuven, Belgium

[8] Ctr Med Austral, Buenos Aires, Argentina

[9] Case Western Reserve Univ, Cleveland, OH USA

[10] Seidman Canc Ctr, UH, Cleveland, OH USA

[11] Ctr Hosp Ardenne, Site Libramont, Libramont, Belgium

[12] Ctr Jean Perrin, Clermont Ferrand, France

[13] Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea

[14] Univ Catholic Louvain, CHU UCL Namur, Site Sainte Elisabeth, Namur, Belgium

[15] Inova Schar Canc Ctr, Fairfax, VA USA

[16] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[17] Bacs Kiskun Megyei Korhaz, Kecskemet, Hungary

[18] IUCT Oncopole, Inst Claudius Regaud, Toulouse, France

[19] Univ Virginia Hlth Syst, Charlottesville, VA USA

[20] Menarini Grp, Florence, Italy

[21] Menarini Grp, Stemline Therapeut, New York, NY USA

[22] Inst Curie, Paris, France

[23] Inst Curie, St Cloud, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1100

引用

页数：1

共 50 条

[1] Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator's choice of endocrine monotherapy for ER+/HER2-advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy: Results of EMERALD phase 3 trial
Bardia, Aditya
Neven, Patrick
Streich, Guillermo
Montero, Alberto J.
Forget, Frederic
Mouret-Reynier, Marie-Ange
Sohn, Joo Hyuk
Vuylsteke, Peter
Harnden, Kathleen K.
Khong, Hung
Kocsis, Judit
Dalenc, Florence
Kaklamani, Virginia
Dillon, Patrick
Babu, Sunil
Waters, Simon
Deleu, Ines
Garcia-Saenz, Jose
Bria, Emilio
Cazzaniga, Marina
Lu, Janice
Aftimos, Philippe
Cortes, Javier
Liu, Shubin
Laurent, Dirk
Conlan, Maureen G.
Bidard, Francois-Clement
CANCER RESEARCH, 2022, 82 (04)
[2] Elacestrant vs fulvestrant or aromatase inhibitor (AI) in phase III trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), vs standard of care (SOC) endocrine monotherapy for ER+/HER2-advanced/metastatic breast cancer (mBC): Subgroup analysis from EMERALD
Aftimos, P. G.
Cortes, J.
Bidard, F. C.
Kaklamani, V.
Bardia, A.
Neven, P.
Streich, G.
Montero, A.
Forget, F.
Reynier, M. A. Mouret
Sohn, J.
Taylor, D.
Harnden, K.
Khong, H.
Kocsis, J.
Dalenc, F.
Dillon, P.
Tonini, G.
Grzegorzewski, K. J.
Lu, J.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S638 - S638
[3] EMERALD: A randomized, open-label, phase 3 trial to evaluate the efficacy and safety of elacestrant (RAD1901), a novel oral selective estrogen receptor degrader (SERD), vs investigator's choice of endocrine therapy for ER+/HER2-advanced breast cancer following CDK4/6 inhibitor therapy
Aftimos, Philippe
Bardia, Aditya
Kaklamani, Virginia G.
Lu, Janice
Bihani, Teeru
Jung, JungAh
Anderson-Villaluz, Alfred T.
Conlan, Maureen G.
Cortes, Javier
CANCER RESEARCH, 2020, 80 (04)
[4] EMERALD: A randomized, open-label, phase III trial to evaluate the efficacy and safety of elacestrant (RAD1901), a novel oral selective estrogen receptor degrader (SERD), vs investigator's choice of endocrine therapy for ER+/HER2-advanced breast cancer following CDK4/6 inhibitor therapy
Bardia, A.
Lu, J.
Kaklamani, V.
Jung, J.
Anderson-Villaluz, A. T.
Conlan, M. G.
Bidard, F-C.
Cortes, J.
Aftimos, P. G.
ANNALS OF ONCOLOGY, 2020, 31 : S80 - S80
[5] SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), in ER+/ HER2-metastatic breast cancer (mBC): Biomarker analyses from a phase I/II study
Chandarlapaty, S.
Bardia, A.
Lord, S.
Linden, H.
Pelekanou, V.
Ternes, N.
Ming, J.
Boutet, V.
Boitier, E.
Gosselin, A.
Lee, J. Sang
Bele, W. Dos-Santos
Protopopov, A.
Celanovic, M.
Bauchet, A-L.
Campone, M.
ANNALS OF ONCOLOGY, 2020, 31 : S351 - S351
[6] Elacestrant vs standard-of-care in ER+/HER2-advanced or metastatic breast cancer (mBC) with ESR1 mutation: key biomarkers and clinical subgroup analyses from the phase 3 EMERALD trial
Bardia, Aditya
O'Shaughnessy, Joyce
Bidard, Francois-Clement
Neven, Patrick
Garcia-Saenz, Jose Angel
Aftimos, Philippe
Cortes, Javier
Lu, Janice
Tonini, Giulia
Theall, Kathy Puvana
Paoli, Alessandro
Kaklamani, Virginia
CANCER RESEARCH, 2024, 84 (09)
[7] Dose-escalation study of SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), in postmenopausal women with ER+/HER2-metastatic breast cancer (mBC).
Bardia, Aditya
Linden, Hannah M.
Ulaner, Gary A.
Chandarlapaty, Sarat
Gosselin, Alice
Doroumian, Severine
Celanovic, Marina
Campone, Mario
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[8] Genomic alterations detected by circulating tumor DNA and correlation with response to treatment with elacestrant, an oral selective estrogen receptor degrader, in phase 1 trials in postmenopausal women with ER+/HER2-advanced/metastatic breast cancer
Bihani, Teeru
Jung, JungAh
Patel, Hitisha K.
Bardia, Aditya
Kabos, Peter
Kaklamani, Virginia
Jager, Agnes
Aftimos, Philippe
Wilks, Sharon
de Vries, Elisabeth
Harb, Wael
Richards, Donald
Weise, Amy
Wesolowski, Robert
van Oordt, Catharina C. W. Menke-van der Houven
Conkling, Paul
Neven, Patrick
Conlan, Maureen G.
CANCER RESEARCH, 2020, 80 (04)
[9] Results from a first-in-human phase Ia/b study of LX-039, an oral selective estrogen receptor (ER) degrader (SERD), in postmenopausal patients with ER+, HER2-advanced breast cancer (ABC)
Shen, W.
Hu, X.
Zhang, J.
Cao, J.
Yao, H.
Wang, X.
Chen, Y.
Du, Y.
Tao, Z.
Wang, L.
Hu, C.
Li, C.
ANNALS OF ONCOLOGY, 2023, 34 : S349 - S349
[10] A first-in-human phase 1 study of SIM0270, a brain-penetrant oral selective estrogen receptor degrader (SERD), in patients with ER+/HER2-locally advanced or metastatic breast cancer
Wu, Jiong
Zhang, Jian
Zhang, Qingyuan
Sun, Yuping
Li, Hongtao
Yin, Yongmei
Shi, Yehui
Li, Wenfeng
Liu, Yunjiang
Yan, Min
Yang, Chen
Zhu, Lili
Yang, Yang
Xue, Liting
CANCER RESEARCH, 2024, 84 (09)

← 1 2 3 4 5 →